- Home
- ANY vs ALGS Comparison
ANY vs ALGS Comparison
Compare ANY & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANY | ALGS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 4 | 82 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 33.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANY | ALGS |
|---|---|---|
| Price | $4.04 | $4.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $30.00 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 5.7M | 121.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,181,000.00 | $2,186,000.00 |
| Revenue This Year | $15.62 | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $5.01 |
| 52 Week High | $6.20 | $13.69 |
Technical Indicators
Market Signals| Indicator | ANY | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 63.62 | 34.64 |
| Support Level | $0.74 | N/A |
| Resistance Level | N/A | $6.82 |
| Average True Range (ATR) | 0.65 | 0.41 |
| MACD | 0.27 | -0.03 |
| Stochastic Oscillator | 54.35 | 7.63 |
Price Performance
Historical ComparisonAbout ANY Sphere 3D Corp.
Sphere 3D Corp is engaged in the Bitcoin mining business. The company has established an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers. It generates revenue from mining and selling Bitcoin.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.